Aromatic amide derivative, and preparation method therefor and use thereof

MYPI2025005414A0Undetermined Publication Date: 2024-09-10ZHEJIANG HISUN PHARMA CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025005414
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-03
Filing Date
2024-03-04
Publication Date
2024-09-10

AI Technical Summary

Technical Problem

Existing KIF18A target inhibitors are relatively limited, especially the lack of effective new drugs for clinical application, and the high expression and function of KIF18A in various cancers have not yet been deeply studied, posing a huge challenge to develop new inhibitors.

Method used

An aromatic amide derivative was developed. Through specific chemical structure design and synthesis methods, a compound with potential pharmaceutical activity was prepared and used as a KIF18A inhibitor. The specific structure includes a specific ring structure and substituent group combination. The compounds formed have potential biological activity.

Benefits of technology

These compounds showed significant inhibitory effects on KIF18A, especially high potency in cell proliferation inhibition and enzyme activity inhibition, and showed good pharmacokinetic properties in mouse pharmacokinetic tests, supporting Its application as a potential antineoplastic drug.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to an aromatic amide derivative, a preparation method therefor, and use of a pharmaceutical composition containing the derivative in medicine. Specifically, the invention relates to an aromatic amide derivative as shown by general formula (I), a preparation method therefor, a pharmaceutically acceptable salt thereof, and a use thereof as a therapeutic agent, in particular a KIF18A inhibitor, wherein the definition of each substituent in general formula (I) is the same as the definition in the description,
Need to check novelty before this filing date? Find Prior Art

Description

Aromatic amide derivatives and their preparation method and use Technical Field

[0001] The present invention relates to an aromatic amide derivative, a preparation method thereof, a pharmaceutical composition containing the derivative, and use of the derivative as a therapeutic agent, in particular as a KIF18A inhibitor. Background Art

[0002] Kinesin molecules are motor proteins that use microtubules as tracks and play an important role in organelle migration, tissue and organ development, signal transduction, mitosis, meiosis, and other processes. Various microtubule-associated proteins (MAPs) in the kinesin-8 family regulate microtubule dynamic instability by affecting microtubule polymerization and depolymerization. KIF18A, a member of the kinesin-8 family, can move toward the positive pole using microtubules as tracks and prefers to bind to longer microtubules. Its activity is length-dependent and affects the length of the spindle, ensuring the timely and smooth alignment of sister chromosomes. Its functions are very similar and conserved across species.

[0003] KIF18A is a molecular motor protein that moves along microtubules toward the plus-end of microtubules. It regulates chromosome midplate assembly by influencing the dynamic instability of microtubule ends, thus functioning during mitosis. During anaphase, the protein is ubiquitinated and degraded, ensuring precise chromosome segregation during mitosis and enabling the successful completion of mitosis and cytokinesis. During early mitosis, KIF18A localization to the plus-end of microtubules near the kinetochore is essential for its function. This localization depends not only on the motor activity of its N-terminus but also on the microtubule-binding tail domain. KIF18A is also subject to reversible phosphorylation / dephosphorylation, but how these post-translational modifications regulate KIF18A function remains understudied. The estrogen receptor ERɑ binds to KIF18A and promotes its transcription, but whether KIF18A is regulated by other transcription factors remains unclear. Therefore, further research is needed into the mechanisms regulating KIF18A's gene transcription. During meiosis, cells lacking KIF18A will be unable to complete meiosis, which will lead to sperm formation disorders and testicular dysplasia in male animals.

[0004] Studies have found that KIF18A protein is highly expressed in a variety of cancers, including but not limited to hepatocellular carcinoma, glioblastoma, colon cancer, breast cancer, lung cancer, bile duct cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer, ovarian cancer, synovial sarcoma, and rhabdomyosarcoma. This suggests that KIF18A is closely associated with the occurrence and progression of tumors and could serve as a target for molecular diagnosis and treatment of various tumors. KIF18A expression is associated with the progression of clinical colorectal cancer. Studies have shown that KIF18A can induce Akt phosphorylation, and knocking out KIF18A in mice significantly promotes cell apoptosis. It is speculated that KIF18A promotes the occurrence and progression of colorectal cancer by activating the PI3K-Akt signaling pathway. KIF18A is also highly expressed in human breast cancer cells, and its overexpression is associated with breast tumor grade, migration, and prognosis. Studies in breast cancer cells have revealed that overexpression of KIF18A leads to the formation of multinucleated cells, while low expression significantly reduces cell proliferation both in vitro and in vivo. This is attributed to KIF18A stabilizing microtubules at their ends and inactivating the PI3K-Akt signaling pathway, leading to apoptosis. Furthermore, KIF18A is upregulated at both the transcriptional and translational levels in lung adenocarcinoma, and abnormal KIF18A expression correlates with clinical and pathological malignancy. KIF18 gene mutations have been observed in lung adenocarcinoma, and its expression is also regulated by DNA copy number. KIF18A knockout inhibits lung adenocarcinoma cell proliferation in vitro and in vivo, inducing apoptosis and G2 / M arrest. Genes that are overexpressed alongside KIF18A are concentrated in cell cycle signaling pathways, thus further investigation of the mechanisms of action of KIF18A in tumors is of great clinical significance.

[0005] No new KIF18A inhibitors have been marketed, and currently only Amgen's AMG-650 has entered Phase I clinical trials. As a cutting-edge research area, KIF18A remains a promising target for further investigation, necessitating continued study of its mechanism of action and the development of new inhibitors.

[0006] Summary of the Invention

[0007] In order to solve the above technical problems, the present invention provides an aromatic amide derivative represented by general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts:

[0008] in:

[0009] Ring A is selected from a 5- to 7-membered heterocyclic group or a 5- to 7-membered heteroaryl group;

[0010] G is selected from

[0011] X1 and X2 are each independently selected from CR aor N atoms;

[0012] Y1, Y2, and Y3 are each independently selected from CR b or N atoms, and at most two of Y1, Y2, and Y3 are N atoms at the same time;

[0013] R a 、R b Each is independently selected from a hydrogen atom, a halogen, a hydroxyl, a cyano group, an alkyl group or an alkoxy group; wherein the alkyl group or the alkoxy group is optionally further substituted by one or more substituents selected from a halogen, a hydroxyl, a cyano group, an alkyl group or an alkoxy group;

[0014] R A are the same or different and are each independently selected from a hydrogen atom, a halogen, a hydroxyl, a cyano group, an alkyl group or an alkoxy group; wherein the alkyl group or the alkoxy group is optionally further substituted by one or more substituents selected from a halogen, a hydroxyl, a cyano group, an alkyl group or an alkoxy group;

[0015] Or, two R A It forms a C(O) with the same carbon atom to which it is attached;

[0016] L1 is selected from a bond or C1-C6 alkylene, wherein the alkylene is optionally further substituted by one or more substituents selected from halogen, hydroxy, cyano or alkoxy, and wherein the one or more methylene groups of the alkylene are optionally replaced by one or more O, S(O) r , C(O) or NR c replaced by;

[0017] R c is selected from a hydrogen atom or an alkyl group;

[0018] L2 is selected from

[0019] R 3 are each independently selected from a hydrogen atom or an alkyl group, wherein the alkyl group is optionally further substituted by one or more substituents selected from halogen, hydroxyl, cyano or alkoxy; R 3 Preferably a hydrogen atom;

[0020] R 1 is selected from hydrogen, cyano, halogen, alkyl, hydroxy, cycloalkyl, heterocyclic, aryl or heteroaryl; wherein the alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent;

[0021] R 4 Selected from cyano, halogen, alkyl, alkenyl, alkynyl, hydroxyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR 5 、-C(O)R 5 、-C(O)OR 5 、-NHC(O)R 5 、-NHC(O)OR 5 、-NR 6 R 7 、-C(O)NR 6 R 7 、-CH2NHC(O)OR 5 、-CH2NR 6 R 7 or -S(O) r R 5 wherein the alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent;

[0022] R 5 Each is independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more hydroxyl groups, halogen groups, nitro groups, cyano groups, alkyl groups, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyl groups, heterocyclic groups, aryl groups, heteroaryl groups, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent;

[0023] R 6 and R 7 Each is independently selected from hydrogen, hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent;

[0024] Or, R 6 and R 7 Together with the atoms to which they are attached, they form a 4-8 membered heterocyclic group, wherein the 4-8 membered heterocyclic group contains one or more N, O or S(O)r, and the 4-8 membered heterocyclic group is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic group, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO2NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent;

[0025] R 8 、R 9 and R 10Each is independently selected from a hydrogen atom, an alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted with one or more substituents selected from a hydroxyl group, a halogen group, a nitro group, an amino group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, a carboxyl group or a carboxylate group;

[0026] n is 0, 1, 2, 3 or 4; and

[0027] r is each independently 0, 1 or 2.

[0028] A preferred embodiment of the present invention provides a compound of formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, which is a compound of formula (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof:

[0029] Ring A, X1, X2, R A 、R 1 、R 4 , L1 and n are as defined in the general formula (I).

[0030] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein:

[0031] L1 is selected from a bond or a C1-C6 alkylene group, wherein the alkylene group is optionally further substituted with one or more hydroxyl groups, and wherein the one or more methylene groups of the alkylene group are optionally replaced with one or more O, S(O) r , C(O) or NR c replaced by;

[0032] r is 2;

[0033] R c is selected from a hydrogen atom or a methyl group.

[0034] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein L1 is selected from a bond, -NHSO2CH2CH2-, -SO2NHCH2CH2-, -SO2-, -CH2SO2-, -NHSO2-, -SO2NH-, -NHC(CH3)2CH2-, -C(O)NHCH2CH2-, -C(O)NHC(CH3)2CH2-, -C(O)N(CH3)CH2CH2-, -CH(CH3)(OH)CH2-, -NHSO2CH(CH3)CH2-, -SO2NHC(CH3)2CH2-, -C(O)NH-, -NHCH2CH2- or -CH2SO2CH2CH2-.

[0035] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, wherein R 1 is selected from hydrogen atom, hydroxyl, alkyl, heterocyclic, cycloalkyl or heteroaryl, wherein the alkyl, heterocyclic, cycloalkyl or heteroaryl is optionally further substituted by one or more substituents selected from hydroxyl or alkyl.

[0036] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, wherein for

[0037] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, wherein for

[0038] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein X1 and X2 are each independently selected from CH.

[0039] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein ring A is selected from:

[0040] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein ring A is selected from:

[0041] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein:

[0042] R A are each independently selected from a hydrogen atom or a methyl group;

[0043] Or, two R A It forms a C(O) with the same carbon atom to which it is attached.

[0044] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein:

[0045] R 4 Each independently selected from 3-10 membered heterocyclic group or C3-C 10 Cycloalkyl, wherein the heterocyclyl or cycloalkyl is optionally further substituted with one or more hydroxyl or halogen.

[0046] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein:

[0047] R 4 Each is independently selected from C2-C6 alkenyl or C1-C6 alkyl, wherein the alkenyl or alkyl is optionally further substituted with one or more hydroxyl groups or halogen.

[0048] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein:

[0049] R 4 for

[0050] A preferred embodiment of the present invention provides a compound of formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, wherein: R 4 for

[0051] In a preferred embodiment of the present invention, the compound of formula (I), (II) or (III) is selected from:

[0052] In a further preferred embodiment of the present invention, the compound of formula (I), (II) or (III) is selected from:

[0053] or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

[0054] Note: If there is a discrepancy between a drawn structure and the name given for that structure, the drawn structure will be given greater weight.

[0055] Furthermore, the present invention provides a pharmaceutical composition comprising an effective dose of a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or a combination thereof.

[0056] The present invention provides a compound of general formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, or a pharmaceutical composition thereof (such as the pharmaceutical composition described in the aforementioned technical solutions) for use as a medicine (i.e., for use in treatment).

[0057] The present invention provides a compound of formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, or its pharmaceutical composition (such as the pharmaceutical composition described in the aforementioned technical solution) for use in the preparation of a KIF18A inhibitor.

[0058] The present invention also provides a use of a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof (e.g., the pharmaceutical composition described in the aforementioned technical solution) in the preparation of a medicament for treating a disease mediated by KIF18A, wherein the disease mediated by KIF18A is preferably cancer; wherein the disease mediated by KIF18A is more preferably selected from hepatocellular carcinoma, glioblastoma, colon cancer, breast cancer, lung cancer, bile duct cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer, ovarian cancer, synovial sarcoma, rhabdomyosarcoma, colorectal cancer and lung adenocarcinoma.

[0059] The present invention further provides a use of a compound of formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, or a pharmaceutical composition thereof (such as the pharmaceutical composition described in the aforementioned technical solution) in the preparation of a drug for treating cancer.

[0060] The present invention provides a compound of general formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, or a pharmaceutical composition thereof (such as the pharmaceutical composition described in the aforementioned technical solution) for use in preparing a medicament for treating hepatocellular carcinoma, glioblastoma, colon cancer, breast cancer, lung cancer, bile duct cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer, ovarian cancer, synovial sarcoma, rhabdomyosarcoma, colorectal cancer and lung adenocarcinoma.

[0061] The present invention further provides a method for preventing and / or treating a disease mediated by KIF18A, comprising administering to a patient a therapeutically effective dose of a compound of formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, or a pharmaceutical composition thereof (e.g., the pharmaceutical composition described in the aforementioned technical solution); wherein the disease mediated by KIF18A is preferably cancer; wherein the disease mediated by KIF18A is more preferably selected from hepatocellular carcinoma, glioblastoma, colon cancer, breast cancer, lung cancer, bile duct cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer, ovarian cancer, synovial sarcoma, rhabdomyosarcoma, colorectal cancer and lung adenocarcinoma.

[0062] The present invention also provides a method for preventing and / or treating cancer, comprising administering to a patient a therapeutically effective dose of a compound of formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, or a pharmaceutical composition thereof (e.g., the pharmaceutical composition described in the aforementioned technical solution).

[0063] The present invention also provides a method for preventing and / or treating hepatocellular carcinoma, glioblastoma, colon cancer, breast cancer, lung cancer, bile duct cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer, ovarian cancer, synovial sarcoma, rhabdomyosarcoma, colorectal cancer and lung adenocarcinoma, comprising administering to a patient a therapeutically effective dose of a compound of general formula (I), (II) or (III) or its stereoisomers, tautomers or pharmaceutically acceptable salts, or a pharmaceutical composition thereof (e.g., the pharmaceutical composition described in the aforementioned technical solution).

[0064] Detailed Description of the Invention

[0065] Unless otherwise stated, some of the terms used in the specification and claims of the present invention are defined as follows:

[0066] "Bond" means that the indicated substituent does not exist and the two end portions of the substituent are directly linked to form a bond.

[0067] "Alkyl" when used as a group or a part of a group refers to a group comprising C1-C 20 A straight chain or branched aliphatic hydrocarbon group. Preferably C1-C10 Alkyl, more preferably C1-C6 alkyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. Alkyl can be substituted or unsubstituted.

[0068] "Alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, representative examples of which are not limited to ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc. C2-C4 alkenyl is preferred. The alkenyl group may be optionally substituted or unsubstituted.

[0069] "Alkynyl" refers to an aliphatic hydrocarbon group containing a carbon-carbon triple bond, which can be straight chain or branched. 10 The alkynyl group of the present invention is substituted or unsubstituted. The alkynyl group of the present invention is substituted or unsubstituted.

[0070] "Alkylene" refers to a saturated C1-C 20 A straight-chain or branched aliphatic hydrocarbon group having two residues derived from the same carbon atom or two different carbon atoms of a parent alkane, preferably C1-C 10 Alkylene, more preferably C1-C6 alkylene. Examples of alkylene groups include, but are not limited to, methylene, 1,1-ethylene, 1,2-ethylene, 1,1-propylene, 1,2-propylene, 1,3-propylene, 1,4-butylene, etc. The alkylene group may be substituted or unsubstituted.

[0071] "Cycloalkyl" refers to a non-aromatic cyclic alkyl group in which one or more of the ring atoms is a carbon atom, including monocyclic, polycyclic, fused, bridged, and spirocyclic rings, preferably having a 5- to 7-membered monocyclic ring or a 7- to 10-membered bicyclic or tricyclic ring. Examples of "cycloalkyl" include, but are not limited to, cyclopropyl, cyclopentyl, and cyclobutyl. Cycloalkyl groups may be substituted or unsubstituted.

[0072] "Spiroalkyl" refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, and one carbon atom (called spiro atom) shared between the monocyclic rings, containing one or more double bonds in the ring, but no ring has a completely conjugated π electron aromatic system. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of spiro atoms shared between the rings, the spiroalkyl is divided into single spiro, double spiro or multiple spiroalkyl groups, preferably single spiro and double spiroalkyl groups, preferably 4 / 5 members, 4 / 6 members, 5 / 5 members or 5 / 6 members. Non-limiting examples of "spiroalkyl" include, but are not limited to, spiro[4.5]decyl, spiro[4.4]nonyl, spiro[3.5]nonyl, spiro[2.4]heptyl, etc.

[0073] "Fused cycloalkyl" refers to a 5- to 18-membered, all-carbon polycyclic group containing two or more cyclic structures sharing a pair of carbon atoms. One or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron aromatic system. It is preferably 6- to 12-membered, and more preferably 7- to 10-membered. Depending on the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl groups, preferably bicyclic or tricyclic, and more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl groups. Non-limiting examples of "fused cycloalkyl" include, but are not limited to, bicyclo[3.1.0]hexyl, bicyclo[3.2.0]hept-1-enyl, bicyclo[3.2.0]heptyl, decahydronaphthyl, tetradecahydrophenanthrenyl, and the like.

[0074] "Bridged cycloalkyl" refers to an all-carbon polycyclic group with 5 to 18 members, containing two or more cyclic structures that share two non-directly connected carbon atoms. One or more rings may contain one or more double bonds, but none of the rings have completely conjugated π electrons. It is an aromatic system with preferably 6 to 12 members, more preferably 7 to 10 members. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged cycloalkyl, preferably bicyclic, tricyclic, or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of "bridged cycloalkyl" include, but are not limited to: (1s,4s)-bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, (1s,5s)-bicyclo[3.3.1]nonyl, bicyclo[2.2.2]octyl, (1r,5r)-bicyclo[3.3.2]decyl, and the like.

[0075] "Heterocyclyl," "heterocycloalkyl," "heterocycle," or "heterocyclic" are used interchangeably herein to refer to a non-aromatic heterocyclic group in which one or more of the ring atoms is selected from nitrogen, oxygen, or S(O) t(wherein t is selected from 0,1 or 2) heteroatoms, including monocycles, polycycles, condensed rings, bridged rings and spirocycles. Preferably there are 5 to 7 membered monocycles or 7 to 10 membered bicyclic or tricyclic rings, which may contain 1,2 or 3 atoms selected from nitrogen, oxygen and / or sulphur. The embodiment of "heterocyclic radical" includes but is not limited to morpholinyl, oxetanyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, 2-oxo-piperidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperazine-2-one, 8-oxa-3-aza-bicyclo [3.2.1] octyl, piperazinyl, hexahydropyrimidine, wait.

[0076] The heterocyclic group may be substituted or unsubstituted.

[0077] "Spiro heterocyclyl" refers to a polycyclic group with 5 to 18 members, two or more ring structures, and one atom shared between the rings, containing one or more double bonds in the ring, but no ring has a completely conjugated π electron aromatic system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) t (wherein t is selected from 0, 1 or 2) heteroatoms, and the remaining ring atoms are carbon. Preferably 6 to 14 members, more preferably 7 to 10 members. According to the number of shared spiro atoms between rings, spiroalkyl is divided into monospiro heterocyclic group, bispiro heterocyclic group or polyspiro heterocyclic group, preferably monospiro heterocyclic group and bispiro heterocyclic group. More preferably, it is 4 yuan / 4 yuan, 4 yuan / 5 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan monospiro heterocyclic group. Non-limiting examples of "spiro heterocyclic group" include but are not limited to: 1,7-dioxaspiro[4.5]decyl, 2-oxa-7-azaspiro[4.4]nonyl, 7-oxaspiro[3.5]nonyl, 5-oxaspiro[2.4]heptyl, wait.

[0078] "Fused heterocyclic group" refers to an all-carbon polycyclic group containing two or more ring structures sharing a pair of atoms, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π-electron aromatic system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) t(wherein t is selected from 0, 1 or 2) heteroatom, and the remaining ring atoms are carbon. Preferably it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic groups. Non-limiting examples of "fused heterocyclic groups" include but are not limited to: octahydropyrrolo[3,4-c]pyrrolyl, octahydro-1H-isoindolyl, 3-azabicyclo[3.1.0]hexyl, octahydrobenzo[b][1,4]dioxin (dioxine), etc.

[0079] "Bridged heterocyclic group" refers to a polycyclic group of 5 to 18 members, containing two or more ring structures, sharing two atoms that are not directly connected to each other, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π-electron aromatic system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) t (wherein t is selected from 0, 1 or 2) heteroatoms, and the remaining ring atoms are carbon. Preferably 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of "bridged heterocyclic groups" include but are not limited to: 2-azabicyclo [2.2.1] heptyl, 2-azabicyclo [2.2.2] octyl, 2-azabicyclo [3.3.2] decyl, etc.

[0080] "Aryl" refers to a carbocyclic aromatic system containing one or two rings, wherein the rings may be joined together in a fused manner. The term "aryl" includes monocyclic or bicyclic aromatic groups, such as phenyl, naphthyl, tetrahydronaphthyl aromatic groups. Preferably, aryl is C6-C 10 The aryl group is more preferably phenyl and naphthyl, and most preferably naphthyl. The aryl group may be substituted or unsubstituted.

[0081] "Heteroaryl" refers to an aromatic 5- to 6-membered monocyclic or 8- to 10-membered bicyclic ring which may contain 1 to 4 atoms selected from nitrogen, oxygen, and / or sulfur. Examples of "heteroaryl" include, but are not limited to, furanyl, pyridyl, 2-oxo-1,2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzodioxolyl, benzothienyl, benzimidazolyl, indolyl, isoindolyl, 1,3-dioxo-isoindolyl, quinolinyl, indazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, isothiazolyl, 1H-1,2,4-triazolyl, 4H-1,2,4 -triazolyl, pyridyl, pyrimidinyl, pyrazin-2(1H)-onyl, pyrimidin-4(3H)-onyl, pyridazin-3(2H)-onyl, 1H-indolyl, 1H-benzo[d]imidazolyl, 1H-pyrrolo[2,3-c]pyridinyl, 3H-imidazo[4,5-c]pyridinyl, isoquinolinyl, quinazolinyl, 2H-isoindolyl, furo[3,2-b]pyridinyl, furo[2,3-c]pyridinyl, thieno[2,3-c]pyridinyl, benzofuranyl, benzo[b]thienyl, 1H-pyrrolo[3,2-b]pyridinyl, 2H-pyrrolo[3,4-c]pyridinyl, wait.

[0082] Heteroaryl groups can be substituted or unsubstituted.

[0083] "Alkoxy" refers to a group consisting of "alkyl-O-." Alkyl is defined herein. C1-C6 alkoxy groups are preferred. Examples include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, and tert-butoxy.

[0084] "Nitro" refers to a -NO2 group.

[0085] "Hydroxy" refers to an -OH group.

[0086] "Halogen" refers to fluorine, chlorine, bromine and iodine.

[0087] "Amino" refers to -NH2.

[0088] "Cyano" refers to -CN.

[0089] "Benzyl" refers to -CH2-phenyl.

[0090] "Carboxyl" refers to -C(O)OH.

[0091] "Carboxylate" refers to a -C(O)O-alkyl group or a -C(O)O-cycloalkyl group, wherein alkyl and cycloalkyl are as defined above.

[0092] "Hydroxyalkyl" refers to an alkyl group substituted with a hydroxy group, wherein alkyl is as defined above.

[0093] "Aminoalkyl" refers to an alkyl group substituted with an amino group, wherein alkyl is as defined above.

[0094] "Haloalkyl" refers to an alkyl group substituted with a halogen, wherein alkyl is as defined above.

[0095] "Haloalkoxy" refers to an alkoxy group substituted with a halogen group, wherein alkoxy is as defined above.

[0096] "DMSO" refers to dimethyl sulfoxide.

[0097] "BOC" refers to tert-butoxycarbonyl.

[0098] "Bn" refers to benzyl.

[0099] "THP" refers to 2-tetrahydropyranyl.

[0100] "TFA" refers to trifluoroacetic acid.

[0101] "Ts" refers to p-toluenesulfonyl.

[0102] "Leaving group", or leaving group, is an atom or functional group that breaks away from a larger molecule in a chemical reaction. It is a term used in nucleophilic substitution reactions and elimination reactions. In a nucleophilic substitution reaction, the reactant attacked by the nucleophile is called the substrate, and the atom or group of atoms that breaks away from the substrate molecule with a pair of electrons is called the leaving group. Groups that easily accept electrons and have a strong ability to withstand negative charges are good leaving groups. The smaller the pKa of the conjugate acid of the leaving group, the easier it is for the leaving group to break away from other molecules. The reason is that when the pKa of its conjugate acid is smaller, the corresponding leaving group does not need to bind to other atoms, and the tendency to exist as an anion (or an electrically neutral leaving group) is enhanced. Common leaving groups include but are not limited to halogens, methylsulfonyl, -OTs or -OH.

[0103] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms, in a group are replaced independently of one another by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and a person skilled in the art can determine (by experiment or theory) which substitutions are possible or impossible without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (e.g., olefinic) bond.

[0104] As used herein, "substituted" or "substituted", unless otherwise specified, means that a group may be substituted by one or more groups selected from the following groups: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, amino, haloalkyl, hydroxyalkyl, carboxyl, carboxylate, =O, -OR 6 、-C(O)R 6 、-C(O)OR 6 、-NHC(O)R 6 、-NHC(O)OR 6 、-NR 7 R 8 、-C(O)NR 7 R 8 、-CH2NHC(O)OR 6 、-CH2NR 7 R 8 or -S(O)rR 6 ;

[0105] R 6 is selected from hydrogen atom, alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein said alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(O)R 9 、-C(O)OR 9 、-OC(O)R 9 、-NR 10 R 11 、-C(O)NR 10 R 11 、-SO2NR 10 R 11 or -NR 10 C(O)R 11 substituted by a substituent;

[0106] R 7 and R 8 Each is independently selected from hydrogen, hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O, -C(O)R 9 、-C(O)OR 9 、-OC(O)R 9 、-NR 10 R11 、-C(O)NR 10 R 11 、-SO2NR 10 R 11 or -NR 10 C(O)R 11 substituted by a substituent;

[0107] Or, R 7 and R 8 Together with the atoms to which they are attached, they form a 4-8 membered heterocyclic group, wherein the 4-8 membered heterocyclic group contains one or more N, O or S(O)r, and the 4-8 membered heterocyclic group is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic group, aryl, heteroaryl, =O, -C(O)R 9 、-C(O)OR 9 、-OC(O)R 9 、-NR 10 R 11 、-C(O)NR 10 R 11 、-SO2NR 10 R 11 or -NR 10 C(O)R 11 substituted by a substituent;

[0108] R 9 、R 10 and R 11 Each is independently selected from a hydrogen atom, an alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted with one or more substituents selected from a hydroxyl group, a halogen group, a nitro group, an amino group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, a carboxyl group or a carboxylate group;

[0109] r is selected from 0, 1 or 2.

[0110] The compounds of the present invention may contain asymmetric centers or chiral centers and therefore exist in different stereoisomeric forms. It is contemplated that all stereoisomeric forms of the compounds of the present invention, including but not limited to diastereomers, enantiomers and atropisomers and geometric (conformational) isomers and mixtures thereof, such as racemic mixtures, are within the scope of the present invention.

[0111] Unless otherwise indicated, structures depicted herein also encompass all isomers (e.g., diastereoisomers, enantiomers, and atropisomers, and geometric (conformational) isomeric forms of such structures; for example, R and S configurations at various asymmetric centers, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, individual stereoisomers as well as enantiomeric mixtures, diastereomeric mixtures, and geometric (conformational) isomeric mixtures of the present compounds are within the scope of the invention.

[0112] "Pharmaceutically acceptable salts" refer to salts of the above compounds that retain their original biological activity and are suitable for pharmaceutical use. Pharmaceutically acceptable salts of the compounds represented by general formula (I) may be metal salts or amine salts formed with suitable acids.

[0113] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredients and thereby exerting their biological activity.

[0114] Synthesis method of the compound of the present invention

[0115] In order to achieve the purpose of the present invention, the present invention adopts the following technical solutions:

[0116] The present invention provides a method for preparing a compound of general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts, the method comprising:

[0117] The compound of formula (IA) undergoes a condensation reaction with the compound (IB), and optionally further undergoes a substitution reaction to obtain the compound of formula (I).

[0118] in:

[0119] L2 is selected from

[0120] Y is selected from hydroxy or chlorine;

[0121] Ring A, X1, X2, Y1, Y2, Y3, L1, G, R 1 、R 3 、R 4 、R A and n are as defined in the general formula (I). DETAILED DESCRIPTION

[0122] The present invention is further described below with reference to the following examples, but these examples are not intended to limit the scope of the present invention.

[0123] Example

[0124] The examples provide the preparation of representative compounds represented by formula (I) and related structural identification data. It must be noted that the following examples are used to illustrate the present invention rather than to limit the present invention. 1 H NMR spectra were obtained using a Bruker instrument (400 MHz), and chemical shifts are expressed in ppm using tetramethylsilane as the internal standard (0.00 ppm). 1 H NMR notation: s = singlet, d = doublet, t = triplet, m = multiplet, br = broadened, dd = doublet of a doublet, dt = doublet of a triplet. Coupling constants, when given, are given in Hz.

[0125] Mass spectra were obtained using LC / MS, and the ionization method could be ESI or APCI.

[0126] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The specification of the silica gel plate used in thin layer chromatography (TLC) is 0.15mm~0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm~0.5mm.

[0127] Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.

[0128] In the following examples, unless otherwise indicated, all temperatures are in degrees Celsius; unless otherwise indicated, various starting materials and reagents were commercially available or synthesized according to known methods, and commercially available materials and reagents were used directly without further purification; unless otherwise indicated, commercial manufacturers include but are not limited to Aldrich Chemical Company, ABCR GmbH & Co. KG, Acros Organics, Guangzan Chemical Technology Co., Ltd. and Jingyan Chemical Technology Co., Ltd.

[0129] CD3OD: deuterated methanol.

[0130] CDCl3: deuterated chloroform.

[0131] DMSO-d6: deuterated dimethyl sulfoxide.

[0132] Argon atmosphere means that the reaction bottle is connected to an argon balloon with a capacity of about 1 L.

[0133] Unless otherwise specified in the examples, the solution in the reaction refers to an aqueous solution.

[0134] The compound was purified using silica gel column chromatography and reverse phase column chromatography, with the eluent system selected from: System A: petroleum ether and ethyl acetate; System B: dichloromethane and methanol; System C: dichloromethane and ethyl acetate; and System D: aqueous trifluoroacetic acid and acetonitrile. The volume ratio of the solvents varied depending on the polarity of the compound and could be adjusted by adding a small amount of an acidic or alkaline reagent, such as acetic acid or triethylamine.

[0135] Example 1

[0136] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0137] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0138] first step

[0139] 7-bromo-5-nitro-2,3-dihydrobenzofuran

[0140] 7-Bromo-5-nitro-2,3-dihydrobenzofuran

[0141] Nitric acid (1.5 mL) was added dropwise to a solution of 7-bromo-2,3-dihydrobenzofuran 1a (700 mg, 3.52 mmol, commercially available) in trifluoroacetic acid (3 mL) and stirred at room temperature for 2 hours. LCMS indicated the reaction was complete. The reaction solution was then slowly added dropwise to water (50 mL), whereupon a pale yellow solid precipitated. This was filtered and the filter cake dried under vacuum to afford 7-bromo-5-nitro-2,3-dihydrobenzofuran 1b (750 mg) in an 87.39% yield.

[0142] MS m / z(ESI):244.0[M+1].

[0143] Step 2

[0144] 4,4-difluoro-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)piperidine

[0145] 4,4-Difluoro-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)piperidine

[0146] 7-Bromo-5-nitro-2,3-dihydrobenzofuran 1b (650 mg, 2.66 mmol) and 4,4-difluoropiperidine 1c (645.24 mg, 5.33 mmol) were dissolved in toluene (20 mL). Palladium acetate (59.80 mg, 266.35 μmol), R-(+)-1,1'-binaphthyl-2,2'-bisdiphenylphosphine (497.54 mg, 799.04 μmol) and cesium carbonate (2.60 g, 7.99 mmol) were added. The atmosphere was replaced with argon three times, the temperature was raised to 100°C, and the mixture was stirred for 16 hours. After the reaction was complete, water (30 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (20 mL × 2). The combined organic phases were washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: System A) to give 4,4-difluoro-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)piperidine 1d (610 mg) in a yield of 80.57%.

[0147] MS m / z(ESI):285.1[M+1].

[0148] Step 3

[0149] 7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-amine

[0150] 7-(4,4-Difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-amine

[0151] Ammonium chloride (559.35 mg, 10.55 mmol) and iron powder (589.38 mg, 10.55 mmol) were added to a mixture of 4,4-difluoro-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)piperidine 1d (300 mg, 1.06 mmol) in water (20 mL) and ethanol (20 mL). The mixture was heated to 80°C and stirred for 2 hours. After the reaction was complete, the mixture was filtered, and ethyl acetate (30 mL) was added to the filtrate. The layers were separated, and the aqueous phase was extracted with ethyl acetate (30 mL x 2). The combined organic phases were washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford 7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-amine 1e (220 mg) in an 81.98% yield.

[0152] MS m / z(ESI):255.1[M+1].

[0153] Step 4

[0154] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-iodo-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0155] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-iodo-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0156] 7-(4,4-Difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-amine 1e (68.34 mg, 268.77 μmol), 2-(6-azaspiro[2.5]octane-6-yl)-4-iodo-benzoic acid 1f (80 mg, 223.97 μmol, prepared according to the method of patent WO2020132648), and 1-methylimidazole (55.84 mg, 671.92 μmol) were added to N,N-dimethylformamide (2 mL), stirred at room temperature for 30 minutes, and (chloro(dimethylamino)methylene)-dimethylammonium hexafluorophosphate (188.53 mg, 671.92 μmol) was added thereto, and stirred at room temperature for 2 hours. After the reaction is complete, the product is concentrated under reduced pressure and the residue is purified by silica gel column chromatography (eluent: System A) to give 1 g (92 mg) of N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-iodo-2-(6-azaspiro[2.5]octan-6-yl)benzamide in a yield of 69.22%.

[0157] MS m / z(ESI):594.4[M+1].

[0158] Step 5

[0159] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0160] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0161] N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-iodo-2-(6-azaspiro[2.5]octan-6-yl)benzamide 1g (80 mg, 134.81 μmol), ethanesulfonamide 1h (22.07 mg, 202.21 μmol, commercially available), 2-(methylamino)acetic acid (18.01 mg, 202.21 μmol), cuprous iodide (7.70 mg, 40.44 μmol) and potassium phosphate trihydrate (179.50 mg, 674.03 μmol) were added to N,N-dimethylformamide (2 mL), replaced with argon, and heated to 100 ° C. and stirred for 6 hours. After the reaction was complete, the reaction solution was filtered and the filtrate was separated by preparative liquid phase separation (separation column AKZONOBEL Kromasil; 250×21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) to give N-(7-(4,4-difluoropiperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octane-6-yl)benzamide 1 (31 mg) with a yield of 40.02%.

[0162] MS m / z(ESI):575.3[M+1].

[0163] 1 H NMR(400MHz,DMSO-d6)δ11.50(s,1H),10.14(s,1H),7.82(d,J=8.5Hz,1H),7 .42(d,J=1.8Hz,1H),7.17(d,J=2.1Hz,1H),7.07–7.01(m,2H),4.54(d,J=8. 7Hz,2H),3.19(qd,J=8.7,7.2,4.1Hz,8H),2.97(t,J=5.2Hz,4H),2.09(tt,J =13.8,5.3Hz,4H),1.55(t,J=5.1Hz,4H),1.20(t,J=7.3Hz,3H),0.35(s,4H).

[0164] Example 2

[0165] N-(7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0166] N-(7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0167] first step

[0168] methyl 4-bromo-2-fluoro-6-methylbenzoate

[0169] Methyl 4-bromo-2-fluoro-6-methylbenzoate

[0170] 4-Bromo-2-fluoro-6-methylbenzoic acid 2a (1.0 g, 4.29 mmol, commercially available) and potassium carbonate (1.19 g, 8.58 mmol) were dissolved in N,N-dimethylformamide (10 mL). Methyl iodide (913.63 mg, 6.44 mmol) was added dropwise at room temperature and stirred for 2 hours. After the reaction was complete, water (20 mL) was added dropwise, and the mixture was extracted with ethyl acetate (50 mL x 2). The combined organic phases were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to provide methyl 4-bromo-2-fluoro-6-methylbenzoate 2b (1.03 g) in a 97.15% yield.

[0171] MS m / z(ESI):247.0[M+1].

[0172] 1 H NMR (400MHz, DMSO-d6) δ7.54 (dd, J=9.5, 1.8Hz, 1H), 7.46 (d, J=1.8Hz, 1H), 3.87 (s, 3H), 2.33 (s, 3H).

[0173] Step 2

[0174] methyl 4-bromo-2-(bromomethyl)-6-fluorobenzoate

[0175] Methyl 4-bromo-2-(bromomethyl)-6-fluorobenzoate

[0176] Methyl 4-bromo-2-fluoro-6-methylbenzoate 2b (500 mg, 2.02 mmol) and azobisisobutyronitrile (33.23 mg, 202.38 μmol) were dissolved in acetonitrile (10 mL). N-bromosuccinimide (468.26 mg, 2.63 mmol) was added at room temperature, and the mixture was heated to 90°C and stirred for 2 hours. After the reaction was complete, water (20 mL) was added dropwise, and the mixture was extracted with ethyl acetate (50 mL x 2). The combined organic phases were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give methyl 4-bromo-2-(bromomethyl)-6-fluorobenzoate 2c (0.53 g) in an 80.34% yield. MS m / z (ESI): 326.9 [M+1].

[0177] Step 3

[0178] 5-bromo-7-fluoro-2-methylisoindolin-1-one

[0179] 5-Bromo-7-fluoro-2-methylisoindolin-1-one

[0180] Methyl 4-bromo-2-(bromomethyl)-6-fluorobenzoate 2c (500 mg, 1.53 mmol) was dissolved in a 4M methylamine dioxane solution (3.83 mL), heated to 40°C, and stirred for 2 hours. After completion of the reaction, water (20 mL) was added dropwise, and the mixture was extracted with ethyl acetate (50 mL x 2). The combined organic phases were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to afford 5-bromo-7-fluoro-2-methylisoindolin-1-one 2d (130 mg) in a 34.72% yield.

[0181] MS m / z(ESI):244.0[M+1].

[0182] Step 4

[0183] 5-bromo-7-(4,4-difluoropiperidin-1-yl)-2-methylisoindolin-1-one

[0184] 5-Bromo-7-(4,4-difluoropiperidin-1-yl)-2-methylisoindolin-1-one

[0185] 5-Bromo-7-fluoro-2-methylisoindolin-1-one 2d (120 mg, 491.68 μmol) and 4,4-difluoropiperidine 1c (9.93 mg, 81.95 μmol) were dissolved in dimethyl sulfoxide (5 mL). N,N-diisopropylethylamine (158.87 mg, 1.23 mmol) was added, and the mixture was heated to 150°C and stirred for 8 hours. After the reaction was complete, water (20 mL) was added dropwise, and the mixture was extracted with ethyl acetate (50 mL x 2). The combined organic phases were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give 5-bromo-7-(4,4-difluoropiperidin-1-yl)-2-methylisoindolin-1-one 2e (150 mg) in an 88.38% yield.

[0186] MS m / z(ESI):344.8[M+1].

[0187] Step 5

[0188] tert-butyl(7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)carbamate

[0189] tert-Butyl (7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)carbamate

[0190] 5-Bromo-7-(4,4-difluoropiperidin-1-yl)-2-methylisoindolin-1-one 2e (140 mg, 405.58 μmol) and tert-butyl carbamate (95.02 mg, 811.17 μmol) were dissolved in 1,4-dioxane (10 mL). Palladium acetate (9.11 mg, 40.56 μmol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (46.94 mg, 81.12 μmol) and cesium carbonate (396.44 mg, 1.22 mmol) were added. Argon was bubbled for 5 minutes, the temperature was raised to 100°C, and the reaction was stirred for 18 hours. After the reaction was complete, water (20 mL) was added dropwise, and the mixture was extracted with ethyl acetate (20 mL × 2). The combined organic phase was washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by silica gel column chromatography (eluent: System A) to give tert-butyl (7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)carbamate 2f (150 mg) in a yield of 96.96%.

[0191] MS m / z(ESI):382.0[M+1].

[0192] Step 6

[0193] 5-amino-7-(4,4-difluoropiperidin-1-yl)-2-methylisoindolin-1-one

[0194] 5-Amino-7-(4,4-difluoropiperidin-1-yl)-2-methylisoindolin-1-one

[0195] Tert-butyl (7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)carbamate 2f (150 mg, 393.27 μmol) was dissolved in hydrochloric acid (4 M, 983.18 μL) and the mixture was heated to 60°C with stirring for 16 hours. After the reaction was complete, water (20 mL) and ethyl acetate (20 mL) were added dropwise. The pH was adjusted to 8-9 with saturated sodium bicarbonate solution. The layers were separated, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford 2 g (110 mg) of 5-amino-7-(4,4-difluoropiperidin-1-yl)-2-methylisoindolin-1-one in a yield of 99.43%.

[0196] MS m / z(ESI):281.9[M+1].

[0197] Step 7

[0198] N-(7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)-4-iodo-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0199] N-(7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)-4-iodo-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0200] 2-(6-Azaspiro[2.5]octan-6-yl)-4-iodo-benzoic acid 1f (130 mg, 363.96 μmol) was dissolved in acetonitrile (10 mL), and 1-methylimidazole (60.50 mg, 727.91 μmol) and tetramethylchlorouronium hexafluorophosphate (204.24 mg, 727.91 μmol) were added. The mixture was stirred at room temperature for 1 hour. 2 g (112.62 mg, 400.35 μmol) of 5-amino-7-(4,4-difluoropiperidin-1-yl)-2-methylisoindolin-1-one was added, and the temperature was raised to 60°C and stirred for 4 hours. After the reaction is complete, the product is concentrated under reduced pressure and the residue is purified by silica gel column chromatography (eluent: System A) to give N-(7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)-4-iodo-2-(6-azaspiro[2.5]octan-6-yl)benzamide 2h (180 mg) in a yield of 79.71%.

[0201] MS m / z(ESI):620.8[M+1].

[0202] Step 8

[0203] N-(7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0204] N-(7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0205] N-(7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)-4-iodo-2-(6-azaspiro[2.5]octan-6-yl)benzamide 2h (100 mg, 161.17 μmol) and ethanesulfonamide 1h (35.18 mg, 322.34 μmol) were dissolved in N,N-dimethylformamide (10 mL), and cuprous iodide (17.89 mg, 80.58 μmol), 2-(methylamino)acetic acid (14.36 mg, 161.17 μmol) and potassium phosphate trihydrate (214.60 mg, 805.84 μmol) were added. Argon was bubbled for 5 min, and the temperature was raised to 100°C and stirred for 18 hours. After the reaction was complete, water (20 mL) was added dropwise, and the mixture was extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was subjected to preparative liquid separation (separation column AKZONOBEL Kromasil; 250×21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) to give N-(7-(4,4-difluoropiperidin-1-yl)-2-methyl-1-oxoisoindolin-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide 2 (45.3 mg) in a yield of 45.92%.

[0206] MS m / z(ESI):602.3[M+1].

[0207] 1 H NMR (400MHz, DMSO-d6) δ11.87(s,1H),10.18(s,1H),7.82(d,J=8.5Hz,1H),7.74(s ,1H),7.17(d,J=2.1Hz,1H),7.11(s,1H),7.05(dd,J=8.5,2.1Hz,1H),4.37(s,2H), 3.20(q,J=7.3Hz,2H),3.30(m,4H),3.00(s,3H),2.97(t,J=5.3Hz,4H),2.15(ddt,J =25.7,18.1,8.9Hz,4H),1.55(t,J=5.3Hz,4H),1.21(t,J=7.3Hz,3H),0.34(s,4H).

[0208] Example 3

[0209] 4-(ethylsulfonamido)-N-(7-(piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0210] 4-(Ethylsulfonamido)-N-(7-(piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0211] first step

[0212] 4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzoic acid

[0213] 4-(Ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzoic acid

[0214] 2-(6-Azaspiro[2.5]octan-6-yl)-4-iodobenzoic acid 1f (1.0 g, 2.80 mmol) and ethanesulfonamide 1h (458.36 mg, 4.20 mmol) were dissolved in N,N-dimethylformamide (10 mL). Cuprous iodide (266.60 mg, 1.40 mmol), sarcosine (249.43 mg, 2.80 mmol), and potassium phosphate (3.73 g, 14.00 mmol) were added. The atmosphere was replaced with argon, and the temperature was raised to 110°C and stirred for 6 hours. The reaction mixture was cooled to room temperature and poured into ice water (200 mL). The pH was adjusted to 6 with dilute hydrochloric acid (2 M). Dichloromethane (200 mL × 3) was added for extraction, and the combined organic phases were washed with saturated sodium chloride solution (50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: System A) to give 4-(ethylsulfonyl)-2-(6-azaspiro[2.5]octane-6-yl)benzoic acid 3a (0.75 g) in a yield of 79.16%.

[0215] MS m / z(ESI):339.4[M+1].

[0216] Step 2

[0217] 1-(5-nitro-2,3-dihydrobenzofuran-7-yl)piperidine

[0218] 1-(5-nitro-2,3-dihydrobenzofuran-7-yl)piperidine

[0219] At room temperature, 7-bromo-5-nitro-2,3-dihydrobenzofuran 1b (488 mg, 2.00 mmol) and piperidine (340.53 mg, 4.00 mmol) were dissolved in toluene (20 mL). Palladium acetate (44.89 mg, 199.97 μmol), R-(+)-1,1'-binaphthyl-2,2'-bisdiphenylphosphine (373.54 mg, 599.90 μmol) and cesium carbonate (1.95 g, 6.00 mmol) were added. The atmosphere was replaced with argon three times, the temperature was raised to 100°C, and the mixture was stirred for 16 hours. The reaction solution was poured into water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic phases were washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (eluent: System A) to give 1-(5-nitro-2,3-dihydrobenzofuran-7-yl)piperidine 3b (310 mg) in a yield of 62%.

[0220] MS m / z(ESI):249.1[M+1].

[0221] Step 3

[0222] 7-(piperidin-1-yl)-2,3-dihydrobenzofuran-5-amine

[0223] 7-(Piperidin-1-yl)-2,3-dihydrobenzofuran-5-amine

[0224] Palladium on carbon (100 mg, 805.55 μmol, 10%) was added to a solution of 1-(5-nitro-2,3-dihydrobenzofuran-7-yl)piperidine 3b (0.2 g, 805.55 μmol) in methanol (20 mL) at room temperature. After hydrogen replacement, the mixture was heated at 50°C and stirred for 4 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to afford 7-(piperidin-1-yl)-2,3-dihydrobenzofuran-5-amine 3c (152 mg) in an 86% yield. The crude product was used directly in the next reaction.

[0225] MS m / z(ESI):219.0[M+1].

[0226] Step 4

[0227] 4-(ethylsulfonamido)-N-(7-(piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0228] 4-(Ethylsulfonamido)-N-(7-(piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0229] Tetramethyluronium chloride hexafluorophosphate (345.98 mg, 664.85 μmol), 4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzoic acid 3a (150 mg, 443.23 μmol), and N,N-diisopropylethylamine (171.85 mg, 1.33 mmol) were added to N,N-dimethylformamide (3 mL) at room temperature and stirred at room temperature for 10 minutes. 7-(piperidin-1-yl)-2,3-dihydrobenzofuran-5-amine 3c (116.11 mg, 531.88 μmol) was added thereto, and the mixture was heated at 65°C with stirring for 2 hours. The reaction solution was poured into water (20 mL) and extracted with ethyl acetate (10 mL×3). The combined organic phases were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated by preparative liquid phase separation (separation column AKZONOBEL Kromasil; 250×21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) to give 4-(ethylsulfonyl)-N-(7-(piperidin-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(6-azaspiro[2.5]octane-6-yl)benzamide 3 (38 mg) in a yield of 16%.

[0230] MS m / z(ESI):539.3[M+1].

[0231] 1 H NMR (400MHz, DMSO-d6) δ11.62(s,1H),10.11(s,1H),7.84(d,J=8.5Hz,1H),7.40 (s,1H),7.17(d,J=2.1Hz,1H),7.04(dd,J=8.4,2.1Hz,1H),6.94(d,J=2.0Hz,1H ),4.50(t,J=8.7Hz,2H),3.23–3.11(m,4H),3.10-3.0(m,4H),3.0-2.90(m,4H), 1.67-1.59(m,4H),1.59-1.46(m,6H),1.20(t,J=7.3Hz,3H),0.40-0.28(m,4H).

[0232] Examples 4-7 were synthesized according to the synthesis method of Examples 1-3 of the present invention. The structures and characterization data of Examples 4-7 are shown in the following table:

[0233] Example 8

[0234] N-(7-cyclopropyl-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0235] N-(7-cyclopropyl-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0236] first step

[0237] 7-cyclopropyl-5-nitro-2,3-dihydrobenzofuran

[0238] 7-Cyclopropyl-5-nitro-2,3-dihydrobenzofuran

[0239] 7-Bromo-5-nitro-2,3-dihydrobenzofuran 1b (0.5 g, 2.05 mmol), cyclopropylboronic acid (351.98 mg, 4.10 mmol), potassium phosphate trihydrate (1.64 g, 6.15 mmol), and tetrakis(triphenylphosphine)palladium (236.75 mg, 204.88 μmol) were added to a mixture of ethanol (2 mL), water (2 mL), and toluene (10 mL) at room temperature. The atmosphere was replaced with argon three times, the temperature was raised to 100°C, and the mixture was stirred for 16 hours. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (eluent: System A) to afford 7-cyclopropyl-5-nitro-2,3-dihydrobenzofuran 8a (255 mg) in a 61% yield.

[0240] MS m / z(ESI):205.9[M+1].

[0241] Step 2

[0242] 7-cyclopropyl-2,3-dihydrobenzofuran-5-amine

[0243] 7-Cyclopropyl-2,3-dihydrobenzofuran-5-amine

[0244] Palladium on carbon (20 mg, 1.24 mmol, 10%) was added to a solution of 7-cyclopropyl-5-nitro-2,3-dihydrobenzofuran 8a (255 mg, 1.24 mmol) in methanol (5 mL) at room temperature. After hydrogen substitution, the mixture was stirred at room temperature for 2 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to afford 7-cyclopropyl-2,3-dihydrobenzofuran-5-amine 8b (195 mg) in a 90% yield. The crude product was used directly in the next reaction.

[0245] MS m / z(ESI):176.1[M+1].

[0246] Step 3

[0247] N-(7-cyclopropyl-2,3-dihydrobenzofuran-5-yl)-4-iodo-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0248] N-(7-cyclopropyl-2,3-dihydrobenzofuran-5-yl)-4-iodo-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0249] Under ice, 2-(6-azaspiro[2.5]octan-6-yl)-4-iodobenzoic acid 1f (0.1 g, 279.97 μmol) and N,N-dimethylformamide (0.1 mL) were added to dichloromethane (3 mL), followed by the slow dropwise addition of oxalyl chloride (71.07 mg, 559.93 μmol) and stirring at room temperature for 2 hours. The mixture was concentrated under reduced pressure, and the residue was added to a solution of 7-cyclopropyl-2,3-dihydrobenzofuran-5-amine 8b (53.96 mg, 307.96 μmol) and triethylamine (84.99 mg, 839.90 μmol) in dichloromethane (3 mL) and stirred at room temperature for 1 hour. The reaction solution was poured into water (10 mL) and extracted with ethyl acetate (10 mL×3). The combined organic phases were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (eluent: System A) to give N-(7-cyclopropyl-2,3-dihydrobenzofuran-5-yl)-4-iodo-2-(6-azaspiro[2.5]octane-6-yl)benzamide 8c (121 mg) in a yield of 84%.

[0250] MS m / z(ESI):514.8[M+1].

[0251] Step 4

[0252] N-(7-cyclopropyl-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0253] N-(7-cyclopropyl-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0254] At room temperature, N-(7-cyclopropyl-2,3-dihydrobenzofuran-5-yl)-4-iodo-2-(6-azaspiro[2.5]octan-6-yl)benzamide 8c (150 mg, 291.60 μmol), ethanesulfonamide 1h (47.74 mg, 437.41 μmol), 2-(methylamino)acetic acid (38.97 mg, 437.41 μmol), cuprous iodide (16.66 mg, 87.48 μmol) and potassium phosphate trihydrate (232.97 mg, 874.81 μmol) were added to N,N-dimethylformamide (2 mL). After argon replacement, the mixture was heated at 100 °C with stirring for 6 h. The reaction solution was poured into water (20 mL) and extracted with ethyl acetate (10 mL×3). The combined organic phases were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was separated by preparative liquid phase separation (separation column AKZONOBEL Kromasil; 250×21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% NH4CO3+H2O, mobile phase B: CH3CN) to obtain N-(7-cyclopropyl-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonyl)-2-(6-azaspiro[2.5]octane-6-yl)benzamide 8 (18 mg) in a yield of 12%.

[0255] MS m / z(ESI):495.9[M+1].

[0256] 1H NMR (400MHz, DMSO-d6) δ11.39(s,1H),10.09(s,1H),7.80(d,J=8.5Hz,1H),7.57(d,J=2.0 Hz,1H),7.15(d,J=2.1Hz,1H),7.02(dd,J=8.5,2.1Hz,1H),6.89(d,J=2.1Hz,1H),4.52(t ,J=8.6Hz,2H),3.23–3.09(m,4H),3.0-2.90(m,4H),1.91(tt,J=8.4,5.2Hz,1H),1.55-1. 48(m,4H),1.20(t,J=7.3Hz,3H),0.97–0.87(m,2H),0.69–0.61(m,2H),0.37-0.31(m,4H).

[0257] Example 9 was synthesized according to the synthesis method of Example 8 of the present invention. The structure and characterization data of Example 9 are shown in the following table:

[0258] Example 10

[0259] 4-(ethylsulfonamido)-N-(7-isobutyl-2,3-dihydrobenzofuran-5-yl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0260] 4-(Ethylsulfonamido)-N-(7-isobutyl-2,3-dihydrobenzofuran-5-yl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0261] At room temperature, 4-(ethylsulfonylamino)-N-(7-(2-methylprop-1-en-1-yl)-2,3-dihydrobenzofuran-5-yl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide 9 (50 mg, 98.10 μmol) and palladium carbon hydrogenation catalyst 10% (10 mg, 98.10 μmol) were added to methanol (3 mL), the atmosphere was replaced with hydrogen three times, and then reacted at room temperature for 4 hours. The reaction solution was filtered, the filter cake was rinsed with methanol (10 mL), and the filtrate was concentrated under reduced pressure to obtain the crude product, which was separated by preparative liquid separation (separation column AKZONOBEL Kromasil; 250×21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) to obtain 4-(ethylsulfonyl)-N-(7-isobutyl-2,3-dihydrobenzofuran-5-yl)-2-(6-azaspiro[2.5]octane-6-yl)benzamide 10 (2.5 mg) in a yield of 5%.

[0262] MS m / z(ESI):512.3[M+1].

[0263] 1 H NMR (400MHz, DMSO-d6) δ11.36 (s, 1H), 10.12 (s, 1H), 7.83 (d, J = 8.5Hz, 1H), 7.68 ( d,J=2.0Hz,1H),7.18(d,J=2.1Hz,1H),7.12–7.00(m,2H),4.49(t,J=8.6Hz,2H), 3.24-3.1(m,4H),3.03-2.94(m,4H),2.37(d,J=7.1Hz,2H),1.95-1.80(m,1H),1. 57-1.49(m,4H),1.21(t,J=7.3Hz,3H),0.89(d,J=6.6Hz,6H),0.37-0.31(m,4H).

[0264] Example 11

[0265] N-(7-(4,4-difluoro-1-hydroxycyclohexyl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0266] N-(7-(4,4-difluoro-1-hydroxycyclohexyl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0267] first step

[0268] 1-(2,3-dihydrobenzofuran-7-yl)-4,4-difluorocyclohexan-1-ol

[0269] 1-(2,3-Dihydrobenzofuran-7-yl)-4,4-difluorocyclohexan-1-ol

[0270] At -78°C, n-butyllithium (965.44 mg, 15.07 mmol, 2.5 M) was added dropwise to a solution of 7-bromo-2,3-dihydrobenzofuran 1a (2 g, 10.05 mmol) in tetrahydrofuran (50 mL). The mixture was stirred at -78°C for 0.5 hour. 4,4-Difluorocyclohexanone 11a (1.48 g, 11.05 mmol) was then added dropwise to the reaction mixture. The mixture was stirred at -78°C for 0.5 hour, then slowly warmed to room temperature and stirred for 2 hours. The reaction was quenched with saturated aqueous ammonium chloride (20 mL), and ethyl acetate (30 mL x 2) was added for extraction. The organic phases were combined, washed with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel chromatography (eluent: System A) to give 1-(2,3-dihydrobenzofuran-7-yl)-4,4-difluorocyclohexan-1-ol 11b (1.6 g) in a yield of 63%.

[0271] MS m / z(ESI):237.1[M-17].

[0272] 1 H NMR (400MHz, DMSO-d6) δ7.34(dd,J=7.8,1.4Hz,1H),7.11(dd,J=7.3,1.3Hz,1H),6.82(t,J=7.5Hz,1H),5.11(s,1H),4. 50(t,J=8.7Hz,2H),3.13(t,J=8.7Hz,2H),2.45-2.30(m,2H),2.30–2.04(m,2H),1.96–1.80(m,2H),1.60-1.50(m,2H).

[0273] Step 2

[0274] 4,4-difluoro-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)cyclohexan-1-ol

[0275] 4,4-Difluoro-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)cyclohexan-1-ol

[0276] Nitric acid (2 mL) was added to a solution of 1-(2,3-dihydrobenzofuran-7-yl)-4,4-difluorocyclohexan-1-ol 11b (500 mg, 1.97 mmol) in acetic acid (5 mL) at room temperature and stirred for 4 hours. The reaction mixture was slowly added dropwise to water (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: System A) to afford 4,4-difluoro-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)cyclohexan-1-ol 11c (274 mg) in a 46% yield.

[0277] MS m / z(ESI):300.1[M+1].

[0278] 1 H NMR (400MHz, DMSO-d6) δ8.34(d,J=2.6Hz,1H),8.16–7.88(m,1H),4.75(t,J=8.9Hz,2H),3.28(t,J= 8.8Hz,2H),2.40(td,J=13.7,4.2Hz,2H),2.29–2.07(m,2H),2.00–1.85(m,2H),1.63–1.49(m,2H).

[0279] Step 3

[0280] 1-(5-amino-2,3-dihydrobenzofuran-7-yl)-4,4-difluorocyclohexan-1-ol

[0281] 1-(5-amino-2,3-dihydrobenzofuran-7-yl)-4,4-difluorocyclohexan-1-ol

[0282] Palladium-on-carbon hydrogenation catalyst (20 mg, 183.78 μmol, 10%) was added to a solution of 4,4-difluoro-1-(5-nitro-2,3-dihydrobenzofuran-7-yl)cyclohexan-1-ol 11c (55 mg, 183.78 μmol) in methanol (5 mL) at room temperature. After hydrogen substitution, the mixture was stirred at room temperature for 16 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to afford 1-(5-amino-2,3-dihydrobenzofuran-7-yl)-4,4-difluorocyclohexan-1-ol 11d (41 mg) in an 83% yield.

[0283] MS m / z(ESI):270.1[M+1].

[0284] Step 4

[0285] N-(7-(4,4-difluoro-1-hydroxycyclohexyl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0286] N-(7-(4,4-difluoro-1-hydroxycyclohexyl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0287] Tetramethyluronium chloride hexafluorophosphate (92.26 mg, 177.29 μmol), 4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzoic acid 3a (40 mg, 118.20 μmol), and N,N-diisopropylethylamine (45.83 mg, 354.59 μmol) were added to N,N-dimethylformamide (3 mL) at room temperature, and the mixture was stirred at room temperature for 10 minutes. 1-(5-amino-2,3-dihydrobenzofuran-7-yl)-4,4-difluorocyclohexan-1-ol 11d (35.01 mg, 130.02 μmol) was added thereto, and the mixture was heated at 65°C with stirring for 2 hours. The reaction solution was poured into water (10 mL) and extracted with ethyl acetate (10 mL×3). The combined organic phases were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated by preparative liquid phase separation (separation column AKZONOBEL Kromasil; 250×21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) to give N-(7-(4,4-difluoro-1-hydroxycyclohexyl)-2,3-dihydrobenzofuran-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octane-6-yl)benzamide 11 (31 mg) in a yield of 41%.

[0288] MS m / z(ESI):590.3[M+1].

[0289] 1H NMR (400MHz, DMSO-d6) δ11.37(s,1H),10.19(s,1H),7.89(d,J=8.5Hz,1H),7.70(s ,1H),7.56(s,1H),7.25(s,1H),7.09(d,J=8.5,2.0Hz,1H),4.53(t,J=8.7Hz,2H), 3.30-3.13(m,4H),3.13-3.0(m,4H),2.39(td,J=13.7,4.2Hz,2H),2.31–2.07(m,2 H),1.98-1.83(m,2H),1.67-1.52(m,6H),1.21(t,J=7.3Hz,3H),0.37-0.31(m,4H).

[0290] Examples 12-21 were synthesized according to the synthesis methods of Examples 1 and 11 of the present invention. The structures and characterization data of Examples 12-21 are shown in the following table:

[0291] Example 22

[0292] N-(7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0293] N-(7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0294] first step

[0295] methyl 3-amino-5-bromo-4-hydroxybenzoate

[0296] 3-Amino-5-bromo-4-hydroxybenzoic acid methyl ester

[0297] At room temperature, methyl 3-bromo-4-hydroxy-5-nitrobenzoate 22a (1.0 g, 3.62 mmol, commercially available) was dissolved in N,N-dimethylformamide (5 mL). Stannous chloride (2.40 g, 12.68 mmol) was added, and the atmosphere was replaced with argon three times. The mixture was stirred at room temperature for 3 hours. Mass spectrometry indicated the reaction was complete. The reaction solution was added dropwise to water (30 mL) and extracted with ethyl acetate (50 mL x 3). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to afford methyl 3-amino-5-bromo-4-hydroxybenzoate 22b (0.85 g) in a 95.36% yield.

[0298] MS m / z(ESI):246.0[M+1].

[0299] Step 2

[0300] methyl 7-bromo-2-methylbenzo[d]oxazole-5-carboxylate

[0301] 7-Bromo-2-methylbenzo[d]oxazole-5-carboxylic acid methyl ester

[0302] Methyl 3-amino-5-bromo-4-hydroxybenzoate 22b (850 mg, 3.45 mmol) was dissolved in 1,1,1-triethoxyethane (8.85 g, 54.55 mmol, 10 mL) at room temperature. 4-Methylbenzenesulfonic acid (59.49 mg, 345.45 μmol) was added. The atmosphere was replaced with argon three times, and the temperature was raised to 80°C. The mixture was stirred for 1 hour, and mass spectrometry indicated the reaction was complete. The product was concentrated to dryness, and the residue was purified by silica gel column chromatography (eluent: System A) to afford methyl 7-bromo-2-methylbenzo[d]oxazole-5-carboxylate 22c (0.75 g) in an 80.39% yield.

[0303] MS m / z(ESI):270.0[M+1].

[0304] Step 3

[0305] methyl 7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazole-5-carboxylate

[0306] 7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazole-5-carboxylic acid methyl ester

[0307] Methyl 7-bromo-2-methylbenzo[d]oxazole-5-carboxylate 22c (750 mg, 2.78 mmol) and 4,4-difluoropiperidine (504.55 mg, 4.17 mmol) were dissolved in toluene (20 mL) at room temperature. Tris(dibenzylideneacetone)dipalladium (127.15 mg, 138.85 μmol), R-(+)-1,1'-binaphthyl-2,2'-bisdiphenylphosphine (172.91 mg, 277.70 μmol) and cesium carbonate (2.71 g, 8.33 mmol) were added. The atmosphere was replaced with argon, the temperature was raised to 100°C, and the mixture was stirred for 18 h. Mass spectrometry showed that the reaction was complete. Water (20 mL) was added to the reaction solution, and the layers were separated by stirring. The product was extracted with ethyl acetate (30 mL × 2). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: System A) to give methyl 7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazole-5-carboxylate 22d (0.65 g) in a yield of 75.43%.

[0308] MS m / z(ESI):311.1[M+1].

[0309] Step 4

[0310] 7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazole-5-carboxylic acid

[0311] 7-(4,4-Difluoropiperidin-1-yl)-2-methylbenzo[d]oxazole-5-carboxylic acid

[0312] Methyl 7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazole-5-carboxylate 22d (600 mg, 1.93 mmol) was dissolved in methanol (5 mL) and tetrahydrofuran (5 mL) at room temperature. Lithium hydroxide solution (2 M, 4.83 mL) was added and stirred at room temperature for 4 h. Mass spectrometry showed that the reaction was complete. After concentration, water (20 mL) was added and the pH was adjusted to 3-4 with hydrochloric acid solution (1 M). The product was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazole-5-carboxylic acid 22e (0.53 g) in a yield of 92.52%.

[0313] MS m / z(ESI):297.1[M+1].

[0314] Step 5

[0315] tert-butyl(7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-yl)carbamate

[0316] tert-Butyl (7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-yl)carbamate

[0317] 7-(4,4-Difluoropiperidin-1-yl)-2-methylbenzo[d]oxazole-5-carboxylic acid 22e (200 mg, 675.06 μmol) was dissolved in tetrahydrofuran (10 mL) at room temperature. Triethylamine (102.46 mg, 1.01 mmol) and diphenylphosphoryl azide (278.67 mg, 1.01 mmol) were added and stirred at room temperature for 3 hours. Mass spectrometry indicated the reaction was complete. Tert-butyl alcohol (50 mL) was added, the temperature was raised to 80°C, and the mixture was stirred for 20 hours. The mixture was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: System A) to afford tert-butyl (7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-yl)carbamate 22f (100 mg) in a 40.32% yield.

[0318] MS m / z(ESI):368.1[M+1].

[0319] Step 6

[0320] 7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-amine

[0321] 7-(4,4-Difluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-amine

[0322] Tert-butyl (7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-yl)carbamate 22f (90 mg, 244.97 μmol) was dissolved in dichloromethane (5 mL) at room temperature. Trifluoroacetic acid (55.86 mg, 489.94 μmol, 5 mL) was added dropwise and stirred at room temperature for 1 hour. Mass spectrometry showed the reaction was complete. The mixture was concentrated to dryness under reduced pressure, added with water (10 mL), and the pH was adjusted to 7-8 with saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and filtered to afford 22 g (50 mg) of 7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-amine in a yield of 76.37%.

[0323] MS m / z(ESI):268.1[M+1].

[0324] Step 7

[0325] N-(7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0326] N-(7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0327] At room temperature, 4-(ethylsulfonylamino)-2-(6-azaspiro[2.5]octan-6-yl)benzoic acid 3a (50 mg, 147.74 μmol) was dissolved in acetonitrile (5 mL), 1-methylimidazole (36.39 mg, 443.23 μmol) and N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (124.36 mg, 443.23 μmol) were added, and the mixture was stirred at room temperature for 1 hour. 7-(4,4-dichloroformamidine) was added. Fluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-amine 22g (51.33mg, 192.07μmol), heated to 60℃, stirred for 1 hour, mass spectrometry showed that the reaction was complete, concentrated to dryness under reduced pressure, added ethyl acetate (30mL), washed with saturated sodium bicarbonate solution (10mL×2), washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was separated by preparative liquid phase separation (separation column AKZONOBEL Kromasil; 250×21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% NH₄CO₃ + H₂O, mobile phase B: CH₃CN) and lyophilized to afford N-(7-(4,4-difluoropiperidin-1-yl)-2-methylbenzo[d]oxazol-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide 22 (5.7 mg) in a 5.2% yield. MS m / z (ESI): 588.3 [M+1].

[0328] 1H NMR (400MHz, DMSO-d6) δ11.70(s,1H),10.15(s,1H),7.84(d,J=8.5Hz,1H),7.75(d,J=1.7Hz,1H),7.18(s,2H),7.04(dd,J=8.5,2.1H z,1H),3.49(t,J=5.7Hz,4H),3.20(q,J=7.3Hz,2H),3.04-2.92(m,4H),2.60(s,3H),2.22–2.10(m,4H),1.66-1.43(m,4H),1.21(t,J= 7.3Hz,3H),0.35(s,4H).

[0329] Example 23

[0330] N-(7-(4,4-difluoropiperidin-1-yl)-1-oxoisoindolin-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0331] N-(7-(4,4-difluoropiperidin-1-yl)-1-oxoisoindolin-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0332] first step

[0333] 5-bromo-7-fluoro-2-(4-methoxybenzyl)isoindolin-1-one

[0334] 5-Bromo-7-fluoro-2-(4-methoxybenzyl)isoindolin-1-one

[0335] Methyl 4-bromo-2-(bromomethyl)-6-fluorobenzoate 2c (1.0 g, 3.07 mmol) and (4-methoxyphenyl)methanamine (631.27 mg, 4.60 mmol) were dissolved in N,N-dimethylformamide (10 mL) at room temperature. N,N-diisopropylethylamine (793.00 mg, 6.14 mmol) was added, and the mixture was heated to 40°C and stirred for 10 hours. Mass spectrometry indicated the reaction was complete. Water (30 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (50 mL x 2). The combined organic phases were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: System A) to afford 5-bromo-7-fluoro-2-(4-methoxybenzyl)isoindolin-1-one 23a (0.79 g) in a yield of 73.53%.

[0336] MS m / z(ESI):349.8[M+1].

[0337] Step 2

[0338] 5-bromo-7-(4,4-difluoropiperidin-1-yl)-2-(4-methoxybenzyl)isoindolin-1-one

[0339] 5-Bromo-7-(4,4-difluoropiperidin-1-yl)-2-(4-methoxybenzyl)isoindolin-1-one

[0340] 5-Bromo-7-fluoro-2-(4-methoxybenzyl)isoindolin-1-one 23a (450 mg, 1.29 mmol) and 4,4-difluoropiperidine (233.48 mg, 1.93 mmol) were dissolved in dimethyl sulfoxide (10 mL) at room temperature. N,N-diisopropylethylamine (332.17 mg, 2.57 mmol) was added, and the temperature was raised to 150°C and stirred for 6 hours. Mass spectrometry showed that the reaction was complete. Water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL × 2). The combined organic phases were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: System A) to give 5-bromo-7-(4,4-difluoropiperidin-1-yl)-2-(4-methoxybenzyl)isoindolin-1-one 23b (0.44 g) in a yield of 75.8%.

[0341] MS m / z(ESI):450.8[M+1].

[0342] Step 3

[0343] tert-butyl(7-(4,4-difluoropiperidin-1-yl)-2-(4-methoxybenzyl)-1-oxoisoindolin-5-yl)carbamate

[0344] tert-Butyl (7-(4,4-difluoropiperidin-1-yl)-2-(4-methoxybenzyl)-1-oxoisoindolin-5-yl)carbamate

[0345] 5-Bromo-7-(4,4-difluoropiperidin-1-yl)-2-(4-methoxybenzyl)isoindolin-1-one 23b (400 mg, 886.32 μmol) and tert-butyl carbamate (207.66 mg, 1.77 mmol) were dissolved in 1,4-dioxane (10 mL) at room temperature. Palladium acetate (19.90 mg, 88.63 μmol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (102.57 mg, 177.26 μmol) and cesium carbonate (866.34 mg, 2.66 mmol) were added. The atmosphere was replaced with argon, the temperature was raised to 100°C, and the mixture was stirred for 18 h. Mass spectrometry showed that the reaction was complete. Water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL × 2). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: System A) to give tert-butyl (7-(4,4-difluoropiperidin-1-yl)-2-(4-methoxybenzyl)-1-oxoisoindolin-5-yl)carbamate 23c (0.4 g) in a yield of 92.57%.

[0346] MS m / z(ESI):488.0[M+1].

[0347] Step 4

[0348] 5-amino-7-(4,4-difluoropiperidin-1-yl)isoindolin-1-one

[0349] 5-Amino-7-(4,4-difluoropiperidin-1-yl)isoindolin-1-one

[0350] Tert-butyl (7-(4,4-difluoropiperidin-1-yl)-2-(4-methoxybenzyl)-1-oxoisoindolin-5-yl)carbamate 23c (400 mg, 820.45 μmol) was dissolved in trifluoroacetic acid (4 mL) at room temperature and stirred for 18 hours. Methanesulfonic acid (2 mL) was added, the temperature was raised to 60°C, and the mixture was stirred for 3 hours. Mass spectrometry indicated the reaction was complete. The mixture was cooled to room temperature and concentrated to dryness. Water (20 mL) was added to the residue, and the pH was adjusted to 8-9 with saturated sodium carbonate solution. The mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford 5-amino-7-(4,4-difluoropiperidin-1-yl)isoindolin-1-one 23d (0.2 g) in a yield of 91.21%.

[0351] MS m / z(ESI):268.1[M+1].

[0352] Step 5

[0353] N-(7-(4,4-difluoropiperidin-1-yl)-1-oxoisoindolin-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0354] N-(7-(4,4-difluoropiperidin-1-yl)-1-oxoisoindolin-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

[0355] 4-(Ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzoic acid 3a (150 mg, 443.23 μmol) was dissolved in acetonitrile (10 mL) at room temperature. 1-Methylimidazole (110.51 mg, 1.33 mmol) and N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (373.09 mg, 1.33 mmol) were added. The mixture was stirred at room temperature for 1 hour. 5-Amino-7-(4,4-difluoropiperidin-1-yl)isoindolin-1-one 23d (130.31 mg, 487.56 μmol) was added. The temperature was raised to 60°C and stirred for 2 hours. Mass spectrometry showed that the reaction was complete. The reaction solution was separated by preparative liquid phase (separation column AKZONOBEL Kromasil; 250×21.2 mm ID; 5 μm, 20 mL / min; mobile phase A: 0.05% NH4CO3+H2O, mobile phase B: CH3CN) to give N-(7-(4,4-difluoropiperidin-1-yl)-1-oxoisoindolin-5-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octane-6-yl)benzamide 23 (43.0 mg) with a yield of 15.75%.

[0356] MS m / z(ESI):588.3[M+1].

[0357] 1H NMR (400MHz, DMSO-d6) δ11.88(s,1H),9.82(s,1H),8.18(s,1H),7.82(d,J=8.4 Hz,1H),7.74(s,1H),7.17(d,J=2.1Hz,1H),7.08(s,1H),7.05(dd,J=8.5,2.1H z,1H),4.28(s,2H),3.44-3.22(m,4H),3.20(q,J=7.3Hz,2H),2.97(t,J=5.2Hz ,4H),2.23-2.09(m,4H),1.61-1.50(m,4H),1.21(t,J=7.3Hz,3H),0.35(s,4H).

[0358] Examples 24-26 were synthesized according to the synthesis methods of Examples 1 and 11 of the present invention. The structures and characterization data of Examples 24-26 are shown in the following table:

[0359] Examples 27-28 were synthesized according to the synthesis method of Example 2 of the present invention. The structures and characterization data of Examples 27-28 are shown in the following table:

[0360] Example 29 was synthesized according to the synthesis method of Example 1 of the present invention. The structure and characterization data of Example 29 are shown in the following table:

[0361] Biological evaluation

[0362] Test Example 1: Determination of the Inhibitory Effect of the Compounds of the Invention on OVCAR-3 Cell Proliferation

[0363] The following method was used to determine the effect of the compounds of the present invention on the proliferation of OVCAR-3 cells. OVCAR-3 cells (containing the TP53R248Q mutation) were purchased from the Cell Resource Center of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and cultured in RPMI 1640 medium containing 10% fetal bovine serum, 100 U penicillin, and 100 μg / mL streptomycin. Cell viability was measured by The assay was performed using the Luminescent Cell Viability Assay Kit (Promega, Cat. No. G7573).

[0364] The experimental method was performed according to the steps in the kit instructions and is briefly described as follows: the test compound was first dissolved in DMSO to prepare a 10mM stock solution, and then diluted with the aforementioned RPMI 1640 medium to prepare the test sample. The final concentration of the compound ranged from 1000nM to 0.015nM. Cells in the logarithmic growth phase were seeded into 96-well cell culture plates at a density of 1000 cells per well and cultured overnight in a 37°C, 5% CO2 incubator. The test compound was then added and cultured for a further 72 hours. After the incubation period, 50μL of CellTiter-Glo detection solution was added to each well, shaken for 5 minutes, and then allowed to stand for 10 minutes. The luminescence value of each sample well was then read on a microplate reader using the Luminescence mode. The percentage inhibition rate of the compound at each concentration point was calculated by comparing it with the value of the control group (0.3% DMSO). Nonlinear regression analysis was then performed in GraphPad Prism 5 software using the logarithm of the compound concentration-inhibition rate to obtain the IC value of the compound for inhibiting cell proliferation. 50 Values ​​are shown in Table 1.

[0365] Table 1 IC of the compounds of the present invention on the inhibition of OVCAR-3 cell proliferation 50 data

[0366] Conclusion: The compounds of the present invention have an IC inhibitory effect on the proliferation of OVCAR-3 cells. 50 <50nM, showing good inhibitory effect.

[0367] Note: The structure of AMG 650 (prepared according to Example 4 of patent publication WO2020132648A1) is as follows:

[0368] Test Example 2: Determination of the Inhibitory Effect of the Compounds of the Invention on HT-29 Cell Proliferation

[0369] The following method was used to determine the effect of the compounds of the present invention on HT-29 cell proliferation. HT-29 cells (containing the TP53R273H mutation) were purchased from the Cell Resource Center of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and cultured in McCoy's 5A medium containing 10% fetal bovine serum, 100 U penicillin, and 100 μg / mL streptomycin. Cell viability was measured by The assay was performed using the Luminescent Cell Viability Assay Kit (Promega, Cat. No. G7573).

[0370] The experimental method was performed according to the steps in the kit instructions and is briefly described as follows: the test compound was first dissolved in DMSO to prepare a 10mM stock solution, then diluted with the aforementioned McCoy's 5A medium to prepare the test sample, with the final compound concentration ranging from 1000nM to 0.015nM. Cells in the logarithmic growth phase were seeded into 96-well cell culture plates at a density of 1000 cells per well and cultured overnight in a 37°C, 5% CO2 incubator. The test compound was then added and cultured for a further 120 hours. After the incubation period, 50μL of CellTiter-Glo detection solution was added to each well, shaken for 5 minutes, and allowed to stand for 10 minutes. The luminescence value of each sample well was then read on a microplate reader using the luminescence mode. The percentage inhibition rate of the compound at each concentration point was calculated by comparing it with the value of the control group (0.3% DMSO). Nonlinear regression analysis was then performed in GraphPad Prism 5 software using the logarithm of compound concentration-inhibition rate to obtain the IC value of the compound for inhibiting cell proliferation. 50 Values ​​are shown in Table 2.

[0371] Table 2 IC of the compounds of the present invention on the inhibition of HT-29 cell proliferation 50 data

[0372] Conclusion: The compounds of the present invention have an IC effect on the proliferation of HT-29 cells. 50 <50nM, showing good inhibitory effect.

[0373] Test Example 3: Test of the Inhibition of KIF18A Enzyme Activity by the Compounds of the Invention

[0374] The following method is used to determine the degree of inhibition of the compound of the present invention on the activity of recombinant human KIF18A enzyme under in vitro conditions. This method uses Promega's ADP-Glo TM Kinase Assay Kit (Cat. No. V9102). Detailed experimental procedures can be found in the kit instructions.

[0375] The experimental process is briefly described as follows: the test compound is first dissolved in DMSO to prepare a stock solution, and then serially diluted using reaction buffer A (15mM Tris, pH 7.5, 10mM MgCl2, 0.01% Pluronic F-68). The final concentration of the test compound in the reaction system ranges from 10000nM to 0.15nM; KIF18A protein and ATP working solution are prepared using reaction buffer B (15mM Tris, pH7.5, 10mM MgCl2, 0.01% Pluronic F-68, 37.5μg / ml tubulin, 1.25μM paclitaxel). The reaction is performed in a 384-well microplate. First, the test compound and recombinant human KIF18A protein (final concentration 100nM, expressed by GenScript) are added to the wells and incubated at room temperature for 20 minutes. Then, ATP solution (from ADP-Glo) is added to the reaction solution. TM Kinase Assay kit component V915A, final concentration 60 μM) and incubate at room temperature for 20 minutes. Subsequently, 5 μL ADP-Glo ​​Reagent was added to the reaction system and incubated at room temperature for 50 minutes. Thereafter, 10 μL Kinase Detection Reagent was added to the reaction system and incubated at room temperature for 30 minutes. After the incubation, the chemiluminescence intensity value of each well was measured in the luminescence mode on the microplate reader. The percentage inhibition rate of the compound at each concentration was calculated by comparing with the luminescence intensity value of the control group (0.1% DMSO), and the nonlinear regression analysis of the compound concentration-inhibition rate was performed using GraphPad Prism 5 software to obtain the IC value of the compound. 50 Values ​​are shown in Table 3.

[0376] Table 3 IC values ​​of the compounds of the present invention for inhibiting KIF18A enzyme activity 50 data

[0377] Conclusion: The compounds of the present invention have an IC inhibitory effect on KIF18A enzyme activity. 50 <500nM, with significant inhibitory effect.

[0378] Test Example 4: Pharmacokinetics of the Compounds of the Invention in Mice

[0379] 1. Experimental Purpose

[0380] ICR mice were used as test animals, and the LC / MS / MS method was used to determine the drug concentrations in plasma at different times after oral administration of the control compound AMG650 and the compounds 1, 18 and 29 of the present invention to study the pharmacokinetic characteristics of the compounds of the present invention in mice.

[0381] 2. Experimental plan

[0382] 2.1 Experimental drugs and animals;

[0383] Reference compound AMG650, compounds 1, 18 and 29.

[0384] ICR mice, male, 27.3-30.3 g, were purchased from Weitonglihua Laboratory Animal Technology Co., Ltd.

[0385] 2.2 Drug preparation

[0386] Weigh an appropriate amount of the test compound and sequentially add appropriate amounts of DMA (N,N-dimethylacetamide), CrEL (polyoxyethylene 35 castor oil), and 5% GS (5% glucose injection). Vortex mix thoroughly by ultrasonication to prepare a 1 mg / mL dosing formulation. DMA, CrEL, and 5% GS are in a ratio of 10:10:80 (v:v:v).

[0387] 2.3 Administration

[0388] ICR mice in each test compound injection group (9 mice in each group) were fasted overnight and then orally administered (PO, compound dosage: 10 mg / kg, administration volume: 10 mL / kg), and were fed 4 hours after administration.

[0389] 3. Operation

[0390] Approximately 0.1 mL of blood was collected intraorbitally before dosing and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours after dosing. Whole blood samples were placed in tubes containing EDTA-K2 for anticoagulation. After collection, the blood samples were placed on ice and centrifuged at 1500 g for 10 minutes to separate the plasma. The collected plasma was stored at –40 to –20°C until analysis.

[0391] The levels of the test compounds in mouse plasma after oral administration were determined by LC-MS / MS.

[0392] 4. Pharmacokinetic parameter results

[0393] The pharmacokinetic parameters of the test compounds are shown in Table 4 below.

[0394] Table 4 Pharmacokinetic parameters of the test compounds in mice

[0395] Conclusion: The plasma concentrations and areas under the curve of compounds 1, 18 and 29 of the present invention are relatively high, and they have good pharmacokinetic properties.

[0396] Test Example 5: Efficacy test of compound 1 of the present invention in mice

[0397] 1. Purpose of the experiment

[0398] The anti-tumor effect of compound 1 of the present invention was evaluated in a BALB / c nude mouse animal model of subcutaneous xenograft of OVCAR-3 human ovarian adenocarcinoma tumor.

[0399] 2. Experimental Animals

[0400] BALB / c nude mice, female, 6-7 weeks old, were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.

[0401] 3. Preparation of test substances

[0402] The vehicle control group was given DMA:CrEL:5% GS=10:10:80 (v:v:v).

[0403] AMG650: Weigh an appropriate amount of AMG-650 and sequentially add appropriate amounts of DMA, CrEL, and 5% GS. Mix thoroughly by ultrasonic vortexing to prepare 0.8 mg / mL and 0.4 mg / mL dosing formulations, respectively. DMA, CrEL, and 5% GS are in a 10:10:80 (v:v:v) ratio.

[0404] Compound 1: Weigh an appropriate amount of compound 1 and sequentially add appropriate amounts of DMA, CrEL, and 5% GS. Mix thoroughly by ultrasonic vortexing to prepare 0.8 mg / mL and 0.4 mg / mL dosing formulations, respectively, with DMA, CrEL, and 5% GS in a ratio of 10:10:80 (v:v:v).

[0405] 4. Obtaining Tumor Mass

[0406] Select appropriate OVCAR-3 tumor-bearing animals, obtain aseptically, obtain 1mm×1mm×1mm OVCAR-3 tumor masses, and place them in normal saline for use in subcutaneous tumor inoculation on the right side of the back of BALB / c nude mice.

[0407] 5. Animal Inoculation and Grouping

[0408] Female BALB / c nude mice were subcutaneously inoculated with OVCAR-3 tumors (approximately 1 mm × 1 mm × 1 mm) on the right side of their back. 3 The mice were randomly divided into groups according to tumor size, with 6 mice in each group.

[0409] 6. Animal Medication and Observation

[0410] Each group of animals was given the test substance once a day at a fixed time according to the animal body weight, orally (po), starting with the first dose on the day of grouping for 22 consecutive days, and the animal body weight was recorded every day.

[0411] Group 1 (G1), solvent control group;

[0412] Group 2 (G2) and Group 3 (G3) received oral administration of AMG-650 at doses of 8 mg / kg and 4 mg / kg, respectively, once a day (QD);

[0413] Group 4 (G4) and Group 5 (G5) were orally administered with compound 1 at doses of 8 mg / kg and 4 mg / kg, respectively, once a day (QD);

[0414] The formation of tumors at the inoculation site of each group of animals was observed, and the tumor volume was measured twice a week and calculated according to the following formula:

[0415] The calculation formulas for tumor volume (TV), relative tumor volume (RTV), relative tumor proliferation rate (T / C) and relative tumor inhibition rate (TGI) are as follows:

[0416] (1)TV(tumor volume)=1 / 2×a×b 2 , where a and b represent the length and width of the tumor, respectively;

[0417] (2)RTV(relative tumor volume)=V t / V0, V0 is the tumor volume measured when grouping, V t is the tumor volume at each measurement;

[0418] (3) T / C (%) = T RTV / C RTV × 100%, where T RTV is the RTV of the treatment group, C RTV is the RTV of the vehicle control group;

[0419] (4) TGI% = (1-T / C) × 100%; where T and C are the relative tumor volumes of the treatment group and the vehicle control group at a specific time point, respectively.

[0420] 7. Results

[0421] Table 5 Pharmacodynamic analysis of the test compounds in each group in the OVCAR-3 human ovarian adenocarcinoma tumor model Note: Data are expressed as "mean ± standard error".

[0422] Conclusion: Under the conditions set in this experiment, in the OVCAR-3 human ovarian adenocarcinoma tumor subcutaneously xenograft BALB / c nude mouse animal model, compared with the solvent and AMG650, the compound 1 of the present invention showed a more significant inhibitory effect on tumor growth at 8 mg / kg and 4 mg / kg.

[0423] Unless otherwise defined, the terms used in the present invention have the same meanings as those commonly understood by those skilled in the art.

[0424] The embodiments described in the present invention are for illustrative purposes only and are not intended to limit the scope of protection of the present invention. Those skilled in the art may make various other substitutions, changes and improvements within the scope of the present invention. Therefore, the present invention is not limited to the above-mentioned embodiments, but is only limited by the claims.

Claims

1. A compound represented by general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof: in: Ring A is selected from a 5- to 7-membered heterocyclic group or a 5- to 7-membered heteroaryl group; G is selected from X 1 , X 2 Each independently selected from CR a or N atoms; Y 1 , Y 2 , Y 3 Each independently selected from CR b or N atoms, and Y 1 , Y 2 , Y 3 At most two of them are N atoms at the same time; R a , R b Each is independently selected from a hydrogen atom, a halogen, a hydroxyl, a cyano group, an alkyl group or an alkoxy group; wherein the alkyl group or the alkoxy group is optionally further substituted by one or more substituents selected from a halogen, a hydroxyl, a cyano group, an alkyl group or an alkoxy group; R A are the same or different and are each independently selected from a hydrogen atom, a halogen, a hydroxyl, a cyano group, an alkyl group or an alkoxy group; wherein the alkyl group or the alkoxy group is optionally further substituted by one or more substituents selected from a halogen, a hydroxyl, a cyano group, an alkyl group or an alkoxy group; Or, two R A It forms a C(O) with the same carbon atom to which it is attached; L 1 Select from key or C 1 -C 6 Alkylene, wherein the alkylene is optionally further substituted by one or more substituents selected from halogen, hydroxyl, cyano or alkoxy, and wherein the one or more methylene groups of the alkylene are optionally substituted by one or more O, S(O) r , C(O) or NR c replaced by; R c is selected from a hydrogen atom or an alkyl group; L 2 Selected from R 3 are each independently selected from a hydrogen atom or an alkyl group, wherein the alkyl group is optionally further substituted by one or more substituents selected from halogen, hydroxyl, cyano or alkoxy; R 3 Preferably a hydrogen atom; R 1 is selected from hydrogen, cyano, halogen, alkyl, hydroxyl, cycloalkyl, heterocyclic, aryl or heteroaryl; The alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups are optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent; R 4 is selected from cyano, halogen, alkyl, alkenyl, alkynyl, hydroxyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR 5 、-C(O)R 5 、-C(O)OR 5 、-NHC(O)R 5 、-NHC(O)OR 5 、-NR 6 R 7 、-C(O)NR 6 R 7 、-CH 2 NHC(O)OR 5 、-CH 2 NR 6 R 7 or -S(O) r R 5 wherein the alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent; R 5 Each is independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic group, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent; R 6 and R 7 Each is independently selected from hydrogen, hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent; Or, R 6 and R 7 Together with the atoms to which they are connected, they form a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic group contains one or more N, O or S(O) r , and the 4- to 8-membered heterocyclic group is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic group, aryl, heteroaryl, =O, -C(O)R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or -NR 9 C(O)R 10 substituted by a substituent; R 8 , R 9 and R 10 Each is independently selected from a hydrogen atom, an alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more substituents selected from a hydroxyl group, a halogen group, a nitro group, an amino group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, a carboxyl group or a carboxylate group; n is 0, 1, 2, 3 or 4; and r is independently 0, 1 or 2.

2. The compound according to claim 1 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is a compound or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof according to general formula (II) or (III): in, Ring A, X 1 , X 2 , R A , R 1 , R 4 , L 1 and n are as defined in claim 1.

3. The compound according to claim 1 or 2, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, in: L 1 Select from key or C 1 -C 6 Alkylene, wherein the alkylene is optionally further substituted by one or more hydroxyl groups, and wherein the one or more methylene groups of the alkylene are optionally replaced by one or more O, S(O) r , C(O) or NR c replaced by; r is 2; R c is selected from a hydrogen atom or a methyl group.

4. The compound according to claim 3 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein L 1 Selected from bonds, -NHSO 2 CH 2 CH 2 -、-SO 2 NHCH 2 CH 2 -、-SO 2 -、-CH 2 SO 2 -、-NHSO 2 -、-SO 2 NH-、-NHC(CH 3 ) 2 CH 2 -、-C(O)NHCH 2 CH 2 -、-C(O)NHC(CH 3 ) 2 CH 2 -、-C(O)N(CH 3 )CH 2 CH 2 -、-CH(CH 3 )(OH)CH 2 -、-NHSO 2 CH(CH 3 )CH 2 -、-SO 2 NHC(CH 3 ) 2 CH 2 -、-C(O)NH-、-NHCH 2 CH 2 -or-CH 2 SO 2 CH 2 CH 2 -.

5. The compound according to claim 1 or 2, or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R 1 is selected from a hydrogen atom, a hydroxyl group, an alkyl group, a heterocyclic group, a cycloalkyl group or a heteroaryl group, wherein the alkyl group, the heterocyclic group, the cycloalkyl group or the heteroaryl group is optionally further substituted by one or more substituents selected from a hydroxyl group or an alkyl group.

6. The compound according to claim 1 or 2, or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein for 7. The compound according to claim 1 or 2, or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein for 8. The compound according to claim 1 or 2, or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein X 1 , X 2 Each is independently selected from CH.

9. The compound according to claim 1 or 2, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from:

10. The compound according to claim 1 or 2, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from:

11. The compound according to claim 1 or 2, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, in: R A are each independently selected from a hydrogen atom or a methyl group; Or, two R A It forms a C(O) with the same carbon atom to which it is attached.

12. The compound according to claim 1 or 2, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, in: R 4 Each independently selected from a 3-10 membered heterocyclic group or a C 3 -C 10 Cycloalkyl, wherein the heterocyclyl or cycloalkyl is optionally further substituted with one or more hydroxyl or halogen.

13. The compound according to claim 1 or 2, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, in: R 4 Each independently selected from C 2 -C 6 Alkenyl or C 1 -C 6 Alkyl, wherein the alkenyl or alkyl is optionally further substituted with one or more hydroxyl or halogen.

14. The compound according to claim 12, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, in: R 4 for 15. The compound according to claim 1 or 2, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, in: R 4 for 16. The compound according to any one of claims 1 to 15, or its stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein the compound is:

17. A pharmaceutical composition comprising an effective dose of the compound according to any one of claims 1 to 16 or its stereoisomer, tautomer or pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, excipient or a combination thereof.

18. Use of the compound according to any one of claims 1 to 16 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 17 in the preparation of a KIF18A inhibitor.

19. Use of the compound according to any one of claims 1 to 16 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 17 in the preparation of a medicament for treating a disease mediated by KIF18A, wherein the disease mediated by KIF18A is preferably cancer.

20. The use according to claim 19, wherein the cancer is selected from hepatocellular carcinoma, glioblastoma, colon cancer, breast cancer, lung cancer, bile duct cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer, ovarian cancer, synovial sarcoma, rhabdomyosarcoma, colorectal cancer or lung adenocarcinoma.

21. Use of the compound according to any one of claims 1 to 16 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 17 in the preparation of a medicament for treating cancer.

22. The method of claim 21, wherein the cancer is selected from hepatocellular carcinoma, glioblastoma, colon cancer, breast cancer, lung cancer, bile duct cancer, pancreatic cancer, prostate cancer, bladder cancer, head cancer, neck cancer, cervical cancer, ovarian cancer, synovial sarcoma, rhabdomyosarcoma, colorectal cancer or lung adenocarcinoma.